Mangoceuticals, Accounts Payable vs Other Assets Analysis

MGRX Stock   2.65  0.15  6.00%   
Mangoceuticals, Common financial indicator trend analysis is infinitely more than just investigating Mangoceuticals, Common recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mangoceuticals, Common is a good investment. Please check the relationship between Mangoceuticals, Common Accounts Payable and its Other Assets accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mangoceuticals, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Accounts Payable vs Other Assets

Accounts Payable vs Other Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mangoceuticals, Common Accounts Payable account and Other Assets. At this time, the significance of the direction appears to have pay attention.
The correlation between Mangoceuticals, Common's Accounts Payable and Other Assets is -0.81. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Other Assets in the same time period over historical financial statements of Mangoceuticals, Common Stock, assuming nothing else is changed. The correlation between historical values of Mangoceuticals, Common's Accounts Payable and Other Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Mangoceuticals, Common Stock are associated (or correlated) with its Other Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Assets has no effect on the direction of Accounts Payable i.e., Mangoceuticals, Common's Accounts Payable and Other Assets go up and down completely randomly.

Correlation Coefficient

-0.81
Relationship DirectionNegative 
Relationship StrengthSignificant

Accounts Payable

An accounting item on the balance sheet that represents Mangoceuticals, Common obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Mangoceuticals, Common are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Other Assets

Most indicators from Mangoceuticals, Common's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mangoceuticals, Common current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mangoceuticals, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Selling General Administrative is likely to rise to about 6.8 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 4.1 M in 2024.
 2010 2023 2024 (projected)
Gross Profit4.9K431.5K240.0K
Total Revenue8.9K731.5K407.2K

Mangoceuticals, Common fundamental ratios Correlations

0.870.991.00.98-0.94-0.831.01.0-0.740.830.981.00.991.00.930.990.940.93-0.730.75-0.65-0.650.75-0.65
0.870.930.820.83-0.71-0.50.860.86-0.390.530.950.880.820.830.630.790.990.63-0.390.33-0.41-0.410.33-0.41
0.990.930.970.96-0.91-0.760.990.99-0.660.771.00.990.970.980.870.960.980.87-0.660.65-0.6-0.60.65-0.6
1.00.820.970.98-0.96-0.861.01.0-0.780.860.960.990.991.00.961.00.90.96-0.770.8-0.67-0.670.8-0.67
0.980.830.960.98-0.98-0.90.980.98-0.830.910.950.980.940.980.930.970.910.93-0.830.79-0.79-0.790.79-0.79
-0.94-0.71-0.91-0.96-0.980.96-0.95-0.950.92-0.97-0.88-0.94-0.91-0.96-0.97-0.96-0.81-0.970.91-0.890.860.86-0.890.86
-0.83-0.5-0.76-0.86-0.90.96-0.83-0.830.99-1.0-0.72-0.81-0.8-0.85-0.94-0.88-0.63-0.940.99-0.960.920.92-0.960.92
1.00.860.991.00.98-0.95-0.831.0-0.750.840.971.00.991.00.940.990.930.94-0.740.76-0.66-0.660.76-0.66
1.00.860.991.00.98-0.95-0.831.0-0.750.840.971.00.991.00.940.990.930.94-0.740.76-0.66-0.660.76-0.66
-0.74-0.39-0.66-0.78-0.830.920.99-0.75-0.75-0.99-0.62-0.73-0.71-0.77-0.9-0.8-0.52-0.91.0-0.960.940.94-0.960.94
0.830.530.770.860.91-0.97-1.00.840.84-0.990.730.820.80.850.930.870.650.93-0.990.94-0.94-0.940.94-0.94
0.980.951.00.960.95-0.88-0.720.970.97-0.620.730.980.950.960.840.940.990.84-0.620.6-0.57-0.570.6-0.57
1.00.880.990.990.98-0.94-0.811.01.0-0.730.820.980.991.00.920.990.950.92-0.720.73-0.64-0.640.73-0.64
0.990.820.970.990.94-0.91-0.80.990.99-0.710.80.950.990.990.940.990.90.94-0.690.76-0.57-0.570.76-0.57
1.00.830.981.00.98-0.96-0.851.01.0-0.770.850.961.00.990.951.00.910.95-0.760.79-0.67-0.670.79-0.67
0.930.630.870.960.93-0.97-0.940.940.94-0.90.930.840.920.940.950.970.751.0-0.880.94-0.75-0.750.94-0.75
0.990.790.961.00.97-0.96-0.880.990.99-0.80.870.940.990.991.00.970.880.97-0.790.83-0.68-0.680.83-0.68
0.940.990.980.90.91-0.81-0.630.930.93-0.520.650.990.950.90.910.750.880.75-0.520.48-0.51-0.510.48-0.51
0.930.630.870.960.93-0.97-0.940.940.94-0.90.930.840.920.940.951.00.970.75-0.880.94-0.75-0.750.94-0.75
-0.73-0.39-0.66-0.77-0.830.910.99-0.74-0.741.0-0.99-0.62-0.72-0.69-0.76-0.88-0.79-0.52-0.88-0.950.960.96-0.940.96
0.750.330.650.80.79-0.89-0.960.760.76-0.960.940.60.730.760.790.940.830.480.94-0.95-0.81-0.811.0-0.81
-0.65-0.41-0.6-0.67-0.790.860.92-0.66-0.660.94-0.94-0.57-0.64-0.57-0.67-0.75-0.68-0.51-0.750.96-0.811.0-0.811.0
-0.65-0.41-0.6-0.67-0.790.860.92-0.66-0.660.94-0.94-0.57-0.64-0.57-0.67-0.75-0.68-0.51-0.750.96-0.811.0-0.811.0
0.750.330.650.80.79-0.89-0.960.760.76-0.960.940.60.730.760.790.940.830.480.94-0.941.0-0.81-0.81-0.81
-0.65-0.41-0.6-0.67-0.790.860.92-0.66-0.660.94-0.94-0.57-0.64-0.57-0.67-0.75-0.68-0.51-0.750.96-0.811.01.0-0.81
Click cells to compare fundamentals

Mangoceuticals, Common Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Mangoceuticals, Stock Analysis

When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.